A Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of TLC-3595 in Subjects With Insulin Resistance
Latest Information Update: 22 Aug 2024
At a glance
- Drugs TLC 3595 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors OrsoBio
Most Recent Events
- 20 Aug 2024 Planned End Date changed from 1 May 2024 to 1 Dec 2024.
- 20 Aug 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Sep 2024.
- 20 Aug 2024 Status changed from recruiting to active, no longer recruiting.